Guy Broadbent has been appointed president and chief executive officer of Xcellerex, Inc., as well as a member of the company’s board of directors. Mr. Broadbent succeeds Joseph Zakrzewski, who served as chairman, president and chief executive officer. Mr. Zakrzewski will continue to serve as chairman of the board.

Mr. Broadbent has 25 years of experience, including in the life sciences sector. He held a number of senior positions at Thermo Fisher Scientific, including president of the Laboratory Products Division, and most recently, senior vice president, corporate development.

Mr. Zakrzewski remarked, “Guy’s skills and experience, including his deep commercial background within the industry, are a great fit with our businesses and will help drive Xcellerex’s future growth. Our biomanufacturing technology has now been validated through its use in over 20 products in development, including Xcellerex’s proprietary Yellow Fever vaccine candidate, currently in a Phase I clinical trial. We successfully commercialized our novel disposable bioreactors and FlexFactory product lines, and grew our complementary services business. I am thankful for the opportunity to have led Xcellerex over the last three years.”